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ABSTRACT
Considerable research has been dedicated to restoring myocardial cell slippage and limiting ventric-
ular remodeling aftermyocardial infarction (MI).Weexamined the ability of a three-dimensional (3D)
engineered fibrin patch filled with human umbilical cord blood-derived mesenchymal stem cells
(UCBMSCs) to induce recovery of cardiac function afterMI. TheUCBMSCsweremodified to coexpress
luciferase and fluorescent protein reporters,mixedwith fibrin, andapplied as an adhesive, viable con-
struct (fibrin-cell patch) over the infarcted myocardium in mice (MI-UCBMSC group). The patch ad-
hered well to the heart. Noninvasive bioluminescence imaging demonstrated early proliferation
and differentiation of UCBMSCswithin the construct in the postinfarctmice in theMI-UCBMSC group.
The implanted cells also participated in the formation of new, functional microvasculature that con-
nected the fibrin-cell patch toboth the subjacentmyocardial tissueand thehost circulatory system.As
revealed by echocardiography, the left ventricular ejection fraction and fractional shortening at sac-
rificewere improved inMI-UCBMSCmiceandweremarkedly reduced inmice treatedwith fibrinalone
and untreated postinfarction controls. In conclusion, a 3D engineered fibrin patch composed of
UCBMSCsattenuated infarct-derived cardiacdysfunctionwhen transplanted locallyoveramyocardial
wound. STEM CELLS TRANSLATIONAL MEDICINE 2015;4:956–966
SIGNIFICANCE
Ischemic heart failure (HF) is the end stage of many cardiovascular diseases, including myocardial in-
farction. Theonly definitive treatment forHF is cardiac transplant,which is hamperedby limitednum-
berofheart donors andgraft rejection. In recent times, cellular cardiomyoplasty hasbeenexpected to
repair infarcted myocardium by implantation of different sources of stem or progenitor cells. How-
ever, low cell survival and myocardial implantation rates have motivated the emergence of novel
approaches with the objective of generating graftable cell-based implants. Here, the potential of
3D engineered fibrin-umbilical cord blood-derived mesenchymal stem cells patches is shown to sig-
nificantly recover lost general functions in post-infarcted mice.
INTRODUCTION
A large amount of research has focused on restor-
ingmyocardial cell slippage and limiting ventricu-
lar remodeling after myocardial infarction (MI)
[1, 2]. Cellular cardiomyoplasty aims to generate
newmyocardial tissue and blood vessels by using
cells with regenerative potential [3–6]. However,
the cell survival is low in the harsh postinjury mi-
lieu; thus, the benefits of cardiomyoplasty for the
recovery of cardiac function have been modest
at best. This has led to the development of newly
designed cell scaffolds or “patches” for myocar-
dial implantation, in which cells with a regenera-
tive capacity are combined with biological and
synthetic materials that can also be supple-
mented with growth or differentiation factors
to generate graftable bioimplants [7–10]. The be-
havior of cells within biomaterial implants can be
monitored with tools, such as bioluminescence
imaging (BLI), that provide noninvasive, real-
time information [11, 12].
Despite significant advances in myocardial re-
vascularization and reperfusion, effective promotion
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TISSUE ENGINEERING AND REGENERATIVE MEDICINE
of angiogenesis is still a challenge for cardiac regeneration
[13–15]. Thus, there is great interest in the identification of
new types of vascular precursors. We recently reported that hu-
man umbilical cord blood (UCB) is a source of multipotent mes-
enchymal stem cells (MSCs) [16–18]. After genetic modi-
fication,UCBMSCswere implanted in live animals andnoninvasively
monitored, which showed differentiation toward the endothelial
lineage and the induction of new vasculature [19].
In the present study, we examined the capacity of a three-
dimensional (3D), engineered fibrin patch, filled with UCBMSCs,
to induce functional vascular connections with the host myocar-
dium and improve cardiac function after MI in mice.
MATERIALS AND METHODS
Cell Culture and Baseline Characterization
Human UCBMSCs were isolated and cultured as described previ-
ously [16, 17]. The cellsweremaintained ina-minimal essentialme-
dium (Sigma-Aldrich, St. Louis,MO, http://www.sigmaaldrich.com)
supplemented with 10% fetal bovine serum (FBS), 1 mM L-gluta-
mine, and 1% penicillin/streptomycin (Gibco, Grand Island, NY,
http://www.lifetechnologies.com).
The cell surface expression of CD29, CD34, CD44, CD45,
CD106, and CD166 was assessed in 33 105 cells incubated with
monoclonal antibodies (mAbs) (10ml of anti-CD29 phycoerythrin
[PE]-conjugated, anti-CD44 fluorescein isothiocyanate [FITC]-
conjugated, anti-CD106 FITC-conjugated, and anti-CD166 PE-
conjugated; 5 ml of anti-CD45 peridinin chlorophyll protein
complex-conjugated and anti-CD34 PE-conjugated; BD Pharmin-
gen, San Diego, CA, http://www.bdbiosciences.com) in 100-ml
phosphate-buffered saline (PBS) (Sigma-Aldrich) containing 1%
FBS for 20 minutes at room temperature. Data were acquired
on an LSRFortessa flow cytometer (BD Biosciences, San Diego,
CA, http://www.bdbiosciences.com), and IgG isotype controls
were used to set gate boundaries for positive cells. Data analysis
was performed with FlowJo software (FlowJo, LLC, Ashland, OR,
http://www.flowjo.com).
Genetic Modification of UCBMSCs
Lentiviral production was performed as described previously [11,
20]. The UCBMSCswere cotransduced (23 106 transducing units
per milliliter, multiplicity of infection = 21, 48 hours) with the fol-
lowing lentiviral vectors: CMVp-RLuc-mRFP1, which contains
a chimeric construct of the Renilla reniformis luciferase (RLuc) re-
porter gene and monomeric red fluorescent protein (mRFP1) in
a PHR lentiviral vector under transcriptional control of the cyto-
megalovirus (CMV) promoter [21]; and CD31p-PLuc-eGFP, a fusion
reporter vector composed of Photinus pyralis luciferase (PLuc) and
enhanced green fluorescent protein (eGFP) coding regions under
the transcriptional control of the 0.25-kb NorI/PstI fragment of
the human CD31 promoter, which has higher transcriptional activ-
ity in endothelial cells than inmonocytic cells [22]. Cells expressing
mRFP1 were selected by fluorescence-activated cell sorting.
Cell Viability Analysis
To determine the cell viability in the fibrin patches, the Live/Dead
viability/cytotoxicity kit (Invitrogen, Carlsbad, CA, http://www.
invitrogen.com) was used according to the manufacturer’s
instructions. In brief, fibrin patches loaded with 1.5 3 106 cells
and cultured for 24 hours under standard culture conditionswere
washed in PBS before staining. The patch constructs were then
analyzed with a confocal microscope (Axio-Observer Z1; Carl
Zeiss, Jena, Germany, http://www.zeiss.com), and tiles-stitching
image postprocessing was applied (Zen Blue software; Carl Zeiss).
Animal Studies
The Animal Experimentation Unit Ethical Committee of the Cata-
lan Institute of Cardiovascular Sciences (ICCC) approved the ani-
mal studies, which complied with the guidelines concerning the
use of animals in research and teaching, as defined by the Guide
for the Care and Use of Laboratory Animals (NIH Publication no.
80-23, revised 1996). All procedures were also performed in ac-
cordance with both national and European legislation: Spanish
Royal Decree RD 53/2013 and EU Directive 2010/63/EU for the
protection of animals used for research experimentation and
other scientific purposes.
Experimental Groups
The studywas performedon35 female SCIDmice (weight, 20–25 g;
Charles River Laboratories, Wilmington, MA, http://www.criver.
com). Themicewere randomly distributed to the following groups:
control-MI (n = 8), MI treated with fibrin alone (MI-fibrin; n = 8),
and MI treated with implantation of the fibrin-cell patches
(MI-UCBMSC; n = 13). A sham groupwithoutMI, but with implan-
tationof the fibrin-cell patcheswasalso included (sham-UCBMSC;
n=6). Theglobalmortality in the experimentwas5.7%, 25% in the
control-MI group and 0% in the other groups; 2 of 35mice died as
a result of surgery.
MI Model and Delivery of the Fibrin-Cell Patch
MI was achieved as described previously [19]. In brief, the mice
were anesthetized with a mixture of O2/isoflurane (2%) (Baxter
International Inc., Deerfield, IL, http://www.baxter.com), intu-
bated, and mechanically ventilated (90 breaths per minute,
0.1 ml tidal volume) using a SAR830/AP small animal ventilator
(CWE, Inc., Ardmore, PA, http://www/cwe-inc.com). An anterior
thoracotomy was performed, and the proximal left anterior
descending (LAD) coronary artery was occluded using a 7-0 silk
suture. The sham-UCBMSCmicewere prepared in the sameman-
ner except that the LAD coronary artery was not occluded before
implantation of the fibrin-cell patches.
To generate the adhesive constructs, Tissucol solution (8 ml;
Baxter International) with 1.5 3 106 transduced cells or culture
mediumwasmixed with 8ml of thrombin solution for jellification
(Tissucol Duo; Baxter International). The fibrin and cells were
maintained under standard culture conditions for 24hours. Fibrin
patches with or without cells were implanted after MI induction
and in the sham-UCBMSCmice using Glubran 2 surgical glue (Car-
diolink Corp., Levittown, NY, http://www.cardiolink.net), which
fulfills the required safety and compatibility standards for exper-
imental animals and human use [23, 24], to seal the edges of the
patch to themyocardium. Themice were sacrificed 4weeks after
the operation. Using cardioplegic solution, the hearts were
arrested in diastole [25] and then excised, fixed in 10% formalin
solution (Sigma-Aldrich), cryopreserved in 30% sucrose in PBS,
embedded in Tissue Tek O.C.T. (Sakura Finetek Europe B.V.,
Alphen aan den Rijn, The Netherlands, http://www.sakura-fintek.
com), and snap-frozen in liquid nitrogen-cooled isopentane for his-
tological analysis.
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Noninvasive BLI
Monitoring of activation of the CD31 promoter or cell number
was performed as previously described [11]. The mice were
injectedeither intraperitoneallywith150ml of luciferin (PLuc sub-
strate; 16.7 mg/ml in physiological serum; Caliper Life Sciences,
PerkinElmer, Hopkinton, MA, http://www.perkinelmer.com)
or through the lateral tail vein with 25 ml of benzyl coelentera-
zine (RLuc substrate; 1 mg/ml in 50% vol/vol propylene
glycol/ethanol; Nanolight Technology, Prolume Ltd., Pinetop,
AZ, http://www.nanolight.com). PLuc and RLuc activities were
monitored under the IVIS Spectrum in vivo photon counting de-
vice (Caliper Life Sciences). Images of Pluc andRlucwere captured
on consecutive days during a 3-week period. The images were
quantified in units of maximum photons per second per square
centimeter per steradian (p/s/cm2/sr) and analyzed using Living
Image 3.10 software (Caliper Life Sciences). The final recorded
light fluxes were expressed as photon counts after subtracting
the background.
Analysis of Cardiac Function
Cardiac function was assessed by echocardiography using an
18–38-MHz linear-array transducer with a digital ultrasound sys-
tem (Vevo 2100 Imaging System; VisualSonics, Toronto, ON, Can-
ada, http://www.visualsonics.com). Measurements were taken
at baseline, 2 days after MI, and 4 weeks after the operation.
The investigators were unaware of the treatment groups. Stan-
dard parasternal long-axis and short-axis views were obtained
inB-modeandM-mode. The left ventricle (LV) end-diastolic diam-
eter (LVEDD) and LV end-systolic diameter (LVESD) were quanti-
fied and the LV ejection fraction (LVEF) was calculated according
to the Teichholz equation [26].
Fluorescence Angiography
Ten minutes before sacrifice, 200 ml of FITC-dextran (10 mg/ml;
Sigma-Aldrich) were injected through the lateral tail vein of the
anesthetized (2% O2/isoflurane) mice. After removal and fixation
for histologic examination, the tissuewas sliced and imaged using
a TCS SP2 laser confocal microscope (Leica, Heerbrugg, Switzer-
land, http://www.leica.com) to analyze the green fluorescent
microvascular structures connecting the myocardium with the
implanted fibrin-cell patches.
Morphometric and Immunohistochemical Examination
The hearts were cross-sectioned from the apex to the base
(10-mm-thick sections spacedevery 300mm). Eight serial cryosec-
tions permousewere stainedwithMasson’s trichrome (collagen,
blue;myocardium, red) formorphometry. To evaluate the infarct
thickness, the LV wall thickness was measured at the thinnest
portion and at the border zones of the infarction. Threemeasure-
ments were made per section to determine the posterior wall
thickness distal to the infarction. Themean value of the eight sec-
tionswas calculated for the thickness parameters. The infarct size
volume, expressed as a percentage of the total LV wall volume,
was calculated by summing the partial scar volumes between
sections. All sections were examined (blindly) and photographed
using a TL RCI stereoscope (Leica).
Immunostaining was performed on the fibrin-cell patch after
24 hours’ incubation to determine the expression levels of CD31
at in vivo implantation. The fibrin-cell patch was incubated with
an anti-CD31 antibody (0.8 mg/ml; Abcam, Cambridge, U.K.,
http://www.abcam.com) for 48 hours at 4°C to ensure its access
to the innermost cells. In these experiments, the cell cytoplasm
was counterstained with phalloidin Atto 488-conjugated (Sigma-
Aldrich). Additional immunoanalysis was performed on cryosec-
tions to detect CD31 and cardiac troponin I using specific mAb
(0.8 mg/ml and 2 mg/ml, respectively; Abcam). The vessel area
was assessed in sections stained with biotinylated GSLI B4 isolec-
tin (Vector Laboratories, Burlingame, CA, http://www.vectorlabs.
com). Nuclei were counterstained with Hoechst 33342 (Sigma-
Aldrich). The images were captured under a laser confocal mi-
croscope (Axio-Observer Z1, Zeiss). Quantitative histological
measurements were made using ImageJ analysis software
(NIH, Bethesda, MD).
Statistical Analysis
The significance of the bioluminescent signal was evaluated
by analysis of variance (ANOVA) using time (baseline, just
after MI, and 30 days after) and treatment (sham-UCBMSC,
control-MI, MI-fibrin, and MI-UCBMSC groups) as factors. A
Greenhouse-Geisser correction was applied. The vessel density,
survival rate, and morphometric data were assessed using one-
wayANOVA. To evaluate the functional parameters, the homoge-
neity of theMIs in all the groups was first determined comparing
thebaseline andpost-MI LVEFand LV fractional shortening (FS) by
ANOVA using time (baseline, post-MI) and treatment as factors.
The LVEF and LVFS differentials between the baseline and presa-
crifice values were evaluated using one-way ANOVA. Pairwise
comparisons between groups were made using Tukey post hoc
analysis for multiple comparisons. The results are presented as
the mean6 SD; p, .05 was considered significant. All analyses
were performed using SPSS Statistics, version 19.0.0.1 (SPSS
software, IBM Corp., Armonk, NY, http://www-01.ibm.com/
software/analytics/spss/).
RESULTS
In these experiments, we sought to track the survival and differ-
entiation of UCBMSCs toward endothelial lineage in vivo using
noninvasive BLI. In order to determine whether established cell
cultures were pure populations ofMSCs, we first assessed the ex-
pression of cell surface antigens by flow cytometry. These analy-
ses ensured that UCBMSC cultures were strictly homogeneous
and did not show baseline expression of either endothelial
(CD34 negative) or hematopoietic (CD45 negative) cell traits
(Fig. 1). The cells were then transduced with a CMVp-RLuc-
mRFP1 lentiviral vector, in which the chimeric protein RLuc-
mRFP1 was expressed under the regulation of the constitutively
active CMV promoter (as a reporter of cell number). Positively
transduced cells were separated by fluorescence-activated cell
sorting and then transduced with a second lentiviral vector,
CD31p-PLuc-eGFP, in which the chimeric protein Pluc-eGFP was
expressed under the control of the inducible promoter of the
human CD31 gene (a protein expressed in the endothelial cell
lineage and used as a marker of vascular differentiation). This
strategy allowed monitoring of the ratio of light produced by
CD31 promoter-regulated PLuc relative to that produced by
the internal standard, the CMV promoter-regulated RLuc. Thus,
changes in cellular differentiation could be evaluated irrespective
of changes in cell number.
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Double-transduced cells were subsequently mixed with fi-
brin, and we assessed the viability and differentiation status of
the 3D patch before in vivo implantation. The cells remained
highly viable in the construct, with viable cells having a fluores-
cence intensity (green) of 74% and dead cells (red) one of only
26% as tested using the Live/Dead viability/cytotoxicity assay
(Invitrogen; Fig. 2A, 2A9). Also, no baseline and/or induction of
CD31 protein expression was corroborated in vitro (Fig. 2B).
Therefore the resulting engineered construct was fixed over
the infarcted area in a mouse model of acute MI. We observed
good attachment of the patch to the heart through macroscopic
analysis (Fig. 3A). Bioluminescence and fluorescence imageswere
taken from the explanted heart of a postinfarcted mouse im-
planted with a fibrin-cell patch (MI-UCBMSC group). Luciferase,
eGFP, and mRFP1 signals were detected in excised hearts, in-
dicating the retention and local presence of the implanted cells
after sacrifice (Fig. 3A).Weekly quantification of photon emission
from the hearts during a 3-week period revealed a 2.3-fold in-
crease in thePLuc/RLuc ratio relative to that at implantation time,
indicative of CD31 promoter activation among the surviving cells
(p = .003; Fig. 3B, 3C). The PLuc/RLuc ratio did not change over
time in the sham-treated mice (Fig. 3C; supplemental online
Fig. 1). Moreover, in theMI-UCBMSC group, CMV-regulated RLuc
activity increased atweek 1 relative to the activity at implantation
(1.5-fold; p = .045) and later decayed to approximately 12%of the
initial value (Fig. 3D). Using a previously reported correlation be-
tween RLuc emission and cell number for our lentivirally cotrans-
duced cells [19], we estimated that the fraction of viable cells
within the patch at 3 weeks after implantation, relative to that
at implantation, was 3%. In the case of the sham-treated mice,
the number of RLuc expressing cells steadily decreased after im-
plantation (Fig. 3D). These results suggest thatMI-derived factors
might induce early proliferation and differentiation of cellswithin
the fibrin patch.
Histological analyses of cross-sections of the excised hearts
bearing fibrin-cell patches corroborated that the constructs were
well adhered to the mouse myocardium, covering the infarcted
scar. In concordance with the BLI findings, we detected the
Figure 1. Analysis of phenotypic traits exhibited by primary umbilical cord blood mesenchymal stem cell (UCBMSC) cultures. Representative
flow cytometric data showing expression levels ofMSC-specific, endothelial-specific (middle), and hematopoietic-specific (bottom) cell surface
markersbyestablishedculturesofUCBMSCs.Gateboundarieswereperformedusing isotype controls (top; overlaidwithmarker inbottomplot),
and dead cells were excluded using viability dye (data not shown). Abbreviations: FITC, fluorescein isothiocyanate; PE, phycoerythrin.
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presence of red and green fluorescence (on activation of the
CD31 promoter-regulated PLuc-eGFP reporter, indicating posi-
tive expression of CD31 protein) human cells within the con-
struct (Fig. 4C). Some doubly labeled red and green fluorescent
UCBMSCs, which expressed CD31 protein, exhibited endothelial
cell morphology and were arranged, forming vessel-like struc-
tures within the fibrin-cell patch in the MI-UCBMSC mice (Fig.
4A–4D, 4F). Additional analysis of vascular structures by GSLI
B4 staining (Vector Laboratories) did not reveal differences in ves-
sel density in the distalmyocardiumor in the border ofMI regions
among the groups (Fig. 4E). After injection of high-molecular-
weight FITC-dextran through the lateral tail vein of livemice, fluo-
rescent angiography was performed to visualize the formation of
new vascular structures, integrated by human mRFP1+ cells and
connected to the host circulatory system, at the interface be-
tween the infarcted myocardium wound and the engrafted
fibrin-cell patch (Fig. 4G). In general, no implanted cells (i.e.,
mRFP1+ cells) were found in the myocardium of the MI-UCBMSC
or sham-treated mice, indicating an absence of migration from
the patch to the underlying heart.
The results from the morphometric analyses of the heart
cross-sections through the infarcted myocardium 4 weeks after
surgery showed that the LV scar thickness (control-MI, 0.16 6
0.08 mm; MI-fibrin, 0.24 6 0.11 mm; and MI-UCBMSC, 0.24 6
0.17 mm; p = . 476) and volume (control-MI, 36.32% 6 12.40%;
MI-fibrin, 40.29% 6 15.23%; and MI-UCBMSC, 35.21% 6
10.96%; p = .836) were similar in the three groups of infarcted
mice (supplemental online Fig. 2).
Functional analyses were performed to determine whether
post-MI implantation of the adhesive fibrin-cell patch had a pos-
itive effect on cardiac function (Table 1). First, to ensure homoge-
neity of the surgical procedure in the studied groups (control-MI,
MI-fibrin, and MI-UCBMSC), a Greenhouse-Geisser analysis was
applied to assess MI size (comparing baseline and post-MI LVEF
and LVFS) [27, 28]. These comparisons revealed no statistically
significant differences among the groups (p = .23 and p = .32
for LVEF and LVFS, respectively; data not shown). LVEF and LVFS
were also calculated as differentials between the values at
30 days postoperatively and those at baseline and compared
among the MI groups (Table 2). This analysis showed that evolu-
tion of both cardiac function parameters was significantly dif-
ferent statistically between the MI-UCBMSC and control-MI/
MI-fibrin mice. In the MI-UCBMSC group, calculations of DLVEF
revealed a clinically relevant (,210%) value (28.7% 6 8.8%).
In particular, 73% of the mice treated with the patches bearing
cells had DLVEF ,210%. In contrast, in the control-MI and MI-
fibrin groups, 100% and 86% of the mice had DLVEF $210%
(221.4% 6 7.7% and 223.1% 6 23%, respectively). Additional
global analysis confirmed that the DLVEF of the MI-UCBMSC
group was significantly different from that of the control-MI
andMI-fibrin groups (p= .03; Fig. 5). Similar resultswereobtained
in the LVFS analysis: only 20% of the MI-UCBMSC and 83% of the
control-MI and 86% of the MI-fibrin mice had a DLVFS $210%
(26.2%6 7%,213.6%6 5.1% and215.1%6 5%, respectively;
Table 2). The differences in DLVFS were also statistically signifi-
cant when compared globally (p = .013; Fig. 5).
DISCUSSION
Although the residual scar size after acuteMI has shrunk owing to
recent innovations, such as evidence-based medicine (aspirin,
b-blockers, angiotensin-converting enzyme inhibitors), and the
incorporation of primary percutaneous coronary interventions,
a portion of the heart still becomes hypokinetic or akinetic.
Cell-based therapies have been proposed for functional tissue re-
placement in these patients [6, 29–31]. However, this requires ef-
ficient delivery and survival of large numbers of cells within the
injured heart to be effective, and this poses amajor challenge [6].
In general, strategiesbasedon thedeliveryof cellswith regen-
erative capacity are feasible and safe; however, they have
exhibited only modest benefits in the recovery of cardiac func-
tion. These limited effects probably result from the adverse me-
chanical stress andhypoxic conditions present in themyocardium
after infarct [32]. The injection of regenerative cells into the in-
farcted area frequently results in low cell engraftment within
the myocardial scar [6, 33–35]. Furthermore, based on our
Figure 2. Assessment of cell viability and differentiation status in the fibrin patch before in vivo implantation. (A):Representative image show-
ing cell viability in a fibrin patch loaded with umbilical cord blood mesenchymal stem cells (UCBMSCs) and cultured for 24 hours in standard
culture conditions. Viable cells are shown in green and dead cells in red, as performed using the Live/Dead viability/cytotoxicity kit (Invitrogen).
(A9):Magnification of a selected peripheral areawith a predominance of viable cells (green). (B): Fibrin patch immunostaining showing absence
of CD31 expression (red) in UCBMSCs. Cell cytoplasm and nucleus were counterstained with Atto 488-phalloidin (green) and 49,6-diamidino-2-
phenylindole, respectively. Scale bars = 1 mm (A) and 20 mm (A9, B).
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experience, most (∼90%) double-labeled (eGFP and Luc) human
adipose tissue-derived MSCs intramuscularly or intravenously
implanted in immunocompromised mice either die or migrate
away from the implantation site and are found (,1%) in the liver
[36]. Thus, novel strategies, such as those based on tissue engi-
neering procedures, are needed [6, 9, 10].
The transplantation of cellularized scaffolds or “patches”over
the infarctedmyocardium protects from cell loss after delivery to
the sites of injury [19, 37, 38]. Currently, none of the biomaterials
tested, whether synthetic or natural, have demonstrated optimal
properties for cardiac tissue repair [9]. Fibrin, the naturally trun-
cated form of fibrinogen, is already widely used in biomedical
applications because of its ability to act as a biocompatible glue,
holding cells in place and stimulating angiogenesis [39–43]. We
used fibrin for the generation of a 3D adhesive patch filled with
UCBMSCs. This patch was subsequently engrafted over the
Figure 3. BLI of the three-dimensional engineered fibrin-cell patches implanted over infarctedmyocardiumwounds. (A): Representative pho-
tographs of a heart excised from a postinfarct mouse at 4 weeks after implantation of an adhesive fibrin-based patch composed of human
UCBMSCs (asterisk) showing PLuc bioluminescence and eGFP and mRFP1 fluorescence emission. (B): BLI of PLuc (top) or RLuc (bottom) from
the implanted UCBMSCs. Bioluminescence images are superimposed on black and white images of recipient mice. The color bars illustrate the
relative light intensities from PLuc and RLuc (low, blue and yellow; high, red and black). Histograms show changes in the PLuc/RLuc ratio (C) and
total RLuc activity (D). p, p = .003 and #, p = .045 (relative to time of implantation), and pp, p, .001. Scale bars = 1 mm. Abbreviations: BLI,
bioluminescence imaging; eGFP, enhanced green fluorescent protein; PLuc, Photinus pyralis luciferase; RLuc, Renilla reniformis luciferase;
p/s/cm2/sr, photons per second per square centimeter per steradian; UCBMSCs, umbilical cord blood mesenchymal stem cells.
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Figure 4. Detection of implanted UCBMSCs and functional vascular structures induced in the infarcted myocardium and fibrin-cell patch in-
terface. (A–C): Representative fluorescence confocal microscope images of a 4-week-old fibrin-cell patch showing, from left to right, red fluo-
rescent human UCBMSCs expressing cytomegalovirus promoter-regulated monomeric red fluorescent protein (mRFP1) (A), green fluorescent
UCBMSCs expressing CD31 promoter-regulated eGFP (B), and cells expressing CD31 protein (C). (D):Merged image of A, B, and C showing
nuclei counterstained with Hoechst 33342. (E): Histogram showing the vessel density expressed as the percentage of the area occupied by
GSLI B4+ cells in sham-UCBMSC, control-MI, MI-fibrin, and MI-UCBMSC mice. (F): GSLI B4 staining (white) showing vessel-like structures
within the fibrin-cell patch at 4weeks after infarction. (G): Vascular structures at the interface (dashed line) between the subjacent infarcted
myocardium wound and engrafted construct. Arrowheads indicate a representative functional microvessel filled with fluorescein isothio-
cyanate-dextran (green) traversing the interface between the host myocardium and cell-seeded fibrin patch (top left). Red fluorescent
UCBMSCs expressing mRFP1 frequently populated the fibrin patch but not the subjacent myocardium (top right). Cardiomyocytes, labeled
using a specific anti-cardiac troponin I antibody (white), exclusively populated the myocardial side of the interface (bottom left). Superimpo-
sition of the three images showed nuclei counterstained with Hoechst 33342 and yellow color stain, resulting from the superposition of red
fluorescent UBCMSCs and green fluorescent dextran (bottom right). Scale bars = 20 mm. Abbreviations: control-MI, myocardial infarction in-
duced but no treatment; eGFP, enhanced green fluorescent protein; MI-fibrin, myocardial infarction treated with fibrin alone; MI-UCBMSC,
myocardial infarction treated with umbilical cord blood mesenchymal stem cells; Sham-UCBMSC, no myocardial infarction but implantation
of fibrin-cell patch.
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infarcted myocardium wound. Recent findings have shown pre-
liminary beneficial effects of human UCBMSCs in the post-MI en-
vironment; however, these cells failed to migrate within the
damaged myocardium [19].
In the present study, we implanted these 3D engineered
constructs and evaluated whether functional vascular connec-
tions with the host myocardium were present as well as the
global cardiac functional recovery. One of the crucial aspects
of cardiac tissue engineering is to generate constructs with
great integration over damaged myocardium. After the im-
plantation procedure, the patch had adhered well to the heart,
and the implanted cells induced the growth of blood vessels
that connected the underlying myocardium and the construct
and promoted reverse remodeling, which was detectable as
a general recovery of cardiac function after MI. The delivered
cells newly expressed CD31 protein (which was absent in the
preimplanted cells) and self-organized within the engrafted
fibrin-cell patch, forming vessel-like structures filled with
high-molecular-weight FITC-dextran, which was injected
through the lateral tail vein of the mice before sacrifice. We
also showed that this newly formed microvasculature was
functional and connected the fibrin-cell patch to both the sub-
jacent myocardial tissue and the host circulatory system. In
contrast, no cells from the patch crossed the interface with
the underlying myocardium.
Noninvasive BLI demonstrated early proliferation and differ-
entiation of the implanted cells within the construct in the MI-
UCBMSCmice. In particular, the activity of the constitutive active
promoter (RLuc) within implanted cells increased at week 1 rela-
tive to implantation but later progressively decayed to appro-
ximately 12% of the initial value. This activity measures the
survival rate of the cells implanted over time. Although the num-
ber of cells in the sham mice declined gradually, the number of
cells in the infarcted mice increased at the beginning, probably
in response to signaling factors generated by the infarct wound.
Such factors might be also responsible for induction of the endo-
thelial phenotype observed by the increase in the PLuc/RLuc ra-
tio. Subsequently, despite our implantation strategy substantially
favoring cell retention comparedwith other conventional cell de-
livery approaches, a proportion of these cells died rapidly after
implantation. A possible reason for this is that the grafted cells
werenotauniformpopulation; thus, only someof themweredes-
tined to differentiate toward the endothelial lineage, and the rest
did not find the right environment to survive. Flow cytometric

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2. Left ventricle ejection fraction and fractional shortening
calculated as differentials between values at 30 days postoperatively
and baseline
Group DLVEF (%) p value DLVFS (%) p value
MI-UCBMSC 28.7 6 8.8 26.2 6 7
Control-MI 221.46 7.7 .02 213.66 5.1 .07
MI-fibrin 223.16 23 .006 215.16 5 .02
Data presented as differential6 SD. p values are referred toMI-UCBMSC
group.
Abbreviations: control-MI, myocardial infarction induced but no
treatment; DLVEF, change in left ventricular ejection fraction;
DLVFS, change in left ventricular fractional shortening; MI-fibrin,
myocardial infarction treated with fibrin alone; MI-UCBMSC,
myocardial infarction treated with umbilical cord blood
mesenchymal stem cells.
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populations were robustly homogeneous because they did not
contain cells that belonged to either the endothelial or hemato-
poietic cell lineages. Moreover, although we observed functional
vessels induced in the infarctedmyocardium and fibrin-cell patch
interface, the implantation environment is generally not well
irrigated and oxygen and nutrients are lacking right after implan-
tation. This hypoxic state is a powerful driver of endothelial differ-
entiation and promotes the selection of cells induced toward the
endothelial lineage. In addition, it is not possible from in vivo BLI
analysis alone to determine whether cell fusion was responsible
for the increase in CD31-regulated light emission. However, al-
though cell fusion events are controversial and at best rare, in
our experiments, a remarkable increase occurred in the amount
of light emitted by CD31-regulated luciferase relative to that pro-
duced by the internal control CMV-regulated luciferase. Although
this would suggest that a large number of implanted cells would
have to have fused with endogenous cells expressing CD31, we
found this was very unlikely, in particular, because the patches
were mainly populated by the implanted cells and no host cells
were found in it.
Furthermore, the mice treated with the 3D engineered fibrin
patch containing UCBMSCs exhibited a progressive increase in
their contractile parameters compared with those treated with
fibrin alone up to 4 weeks after implantation. These data are in
agreementwith data fromprevious studies, which demonstrated
that an increased infarct wall thickness, using an acellular scaf-
fold, was insufficient for preventing postinfarction LV remodeling
[44–46]. Thus, our results suggest that additional multipotent
UCBMSCs prevent such remodeling. Myocardial remodeling, as
measuredby the recovery of functional LVparameters to baseline
Figure 5. Echocardiographic evaluation of cardiac function. Histograms representingDLVEF (A) andDLVFS (B) frombaseline to before sacrifice
(30 days). Differences between groups were globally estimated using one-way analysis of variance. (C): Representative M-mode echocardio-
graphic images in the parasternal long axis view. Abbreviations: control-MI, myocardial infarction induced but no treatment; DLVEF, change in
left ventricular ejection fraction; DLVFS, change in left ventricular fractional shortening; MI-fibrin, myocardial infarction treated with fibrin
alone;MI-UCBMSC, myocardial infarction treated with umbilical cord bloodmesenchymal stem cells; Sham-UCBMSC, nomyocardial infarction
but implantation of fibrin-cell patch.
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levels, was reversed when fibrin-UCBMSC patches were applied.
In particular, the global beneficial effects of the fibrin-cell patch
were not due to a local reduction in the infarct size; rather, they
included remote effects on the noninfarctedmyocardium and on
the infarct/border areas. In support of this observation, a “sys-
temsbiology” approach previously showed that acuteMI induced
substantial gene expression changes in remote myocardial regions
in swine [47]. Furthermore, because many research efforts have
focused on restoring myocardial damage after MI through cell
therapy approaches, our findings should be interpreted with
some considerations in respect to clinical significance. Because
fibrin-cell patches were applied immediately after induction of
the infarct, the potential benefits should be associated with mit-
igation rather than injury improvement.
CONCLUSION
We used a strategy based on the combination of noninvasive BLI
and histological procedures, supported by the evaluation of car-
diac functional parameters, to evaluate the benefits induced by
a 3D fibrin-based patch, whichwas engineered as a UCBMSC sup-
port and transplanted locally over infarctedmyocardium inmice.
Compared with conventional strategies of cell administration,
which have been associated with low cell survival, the construct
used in our study conferred a favorable environment for cell via-
bility and maintenance of the implanted cells at the myocardial
infarct site, allowing them to exert effects for at least 3 weeks af-
ter implantation. Our systemalso has other benefits. The capacity
to continually and noninvasively visualize the cellular processes
and other biological interactions using BLI reduces the use of
experimental animals and improves reproducibility. The use of
luciferase reporters allows good quantification, because the cor-
relation between the signal intensity and cell numbers is good
[19, 48]. In our model, the correlational interpretation of the
imaging and cardiac function data is complex. A tentative inte-
grated interpretation of our data is that as patches with cells
are implanted, the degradation of fibrin and the release of growth
factors from dying and living cells produce an overall positive ef-
fect on the myocardium, observed as functional improvements.
However, our results appear to indicate that the effects on cell
proliferation, loss, and differentiation observed by BLI could de-
creaseover time. The factors releasedby the cells, including those
differentiating, might be responsible for sustained improvement
in myocardial repair, in particular, in the vascular system. The
implanted cells promoted and participated in the functional vas-
cularization of the construct, but not of the subjacent or distal
myocardial tissue, and did not significantly increase the infarct
wall thickness or reduce scar volume. However, the infarcted
mice treated with this fibrin-cell patch demonstrated postinfarc-
tion reverse remodeling that appeared as a general recovery of
lost myocardial function.
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33 Assmus B, Schächinger V, Teupe C et al.
Transplantation of progenitor cells and regen-
eration enhancement in acute myocardial in-
farction (TOPCARE-AMI). Circulation 2002;
106:3009–3017.
34 Barbash IM, Chouraqui P, Baron J et al.
Systemicdeliveryof bonemarrow-derivedmes-
enchymal stem cells to the infarcted myocar-
dium: Feasibility, cell migration, and body
distribution. Circulation 2003;108:863–868.
35 Freyman T, Polin G, Osman H et al. A
quantitative, randomized study evaluating
threemethods of mesenchymal stem cell deliv-
ery following myocardial infarction. Eur Heart J
2006;27:1114–1122.
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40 Bensäıd W, Triffitt JT, Blanchat C et al. A
biodegradable fibrin scaffold for mesenchymal
stem cell transplantation. Biomaterials 2003;
24:2497–2502.
41 Christman KL, Vardanian AJ, Fang Q et al.
Injectable fibrin scaffold improves cell transplant
survival, reduces infarct expansion, and induces
neovasculature formation in ischemic myocar-
dium. J Am Coll Cardiol 2004;44:654–660.
42 Leor J, Amsalem Y, Cohen S. Cells, scaf-
folds, andmolecules for myocardial tissue engi-
neering. Pharmacol Ther 2005;105:151–163.
43 Ahmed TA, Dare EV, Hincke M. Fibrin: A
versatile scaffold for tissue engineering applica-
tions. Tissue Eng Part B Rev 2008;14:199–215.
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